Ceryvyn Therapeutics (ASX:CYV) Institutional Ownership: 7.80% (As of Jul. 11, 2026)


What is Ceryvyn Therapeutics Institutional Ownership?

Ceryvyn Therapeutics ASX:CYV -7.69% Institutional Ownership is 7.80% as of Jul. 11, 2026. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ceryvyn Therapeutics's institutional ownership is 7.80%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ceryvyn Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ceryvyn Therapeutics's Float Percentage Of Total Shares Outstanding is 74.81%.

Ceryvyn Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Institutional Ownership Chart

Ceryvyn Therapeutics Historical Data

The historical data trend for Ceryvyn Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 7.72 7.72 7.72 7.81 7.79 7.79 7.81 7.80 7.80 7.80

Ceryvyn Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 7.80% mean?
Ceryvyn Therapeutics (ASX:CYV) has a Institutional Ownership of 7.80% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics' Institutional Ownership too high?
Ceryvyn Therapeutics' current Institutional Ownership is 7.80%.
How does Ceryvyn Therapeutics' Institutional Ownership compare to VRTX and REGN?
Ceryvyn Therapeutics' Institutional Ownership of 7.80% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current Institutional Ownership is 7.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Institutional Ownership of 7.80%. The current Institutional Ownership is 7.80%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current Institutional Ownership is 7.80% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.